Related Experiment Videos

Infliximab as first-line therapy for Crohn's disease is premature

Gordon R Greenberg¹

¹Department of Medicine, Mt Sinai Hospital, University of Toronto, Ontario, Canada. ggreenberg@mtsinai.on.ca

Inflammatory Bowel Diseases

|February 12, 2002

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Preoperative Anti-tumor Necrosis Factor Therapy in Patients with Ulcerative Colitis Is Not Associated with an Increased Risk of Infectious and Noninfectious Complications After Ileal Pouch-anal Anastomosis.

Inflammatory bowel diseases·2016

Infliximab to Treat Refractory Inflammation After Pelvic Pouch Surgery for Ulcerative Colitis.

Journal of Crohn's & colitis·2016

Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial.

Lancet (London, England)·2015

Predictors of Outcome in Ulcerative Colitis.

Inflammatory bowel diseases·2015

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease.

Gut·2014

Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease.

Gastroenterology·2013

See all related articles